Proteasome inhibition represses ERα gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

(2009) John F.R. Robertson et al.   JOURNAL OF CLINICAL ONCOLOGY

miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor   mRNA

(2009) D. P. Pandey et al.   MOLECULAR AND CELLULAR BIOLOGY

Repression of ESR1 through Actions of Estrogen Receptor Alpha and Sin3A at the Proximal Promoter

(2009) S. J. Ellison-Zelski et al.   MOLECULAR AND CELLULAR BIOLOGY

RelB NF- B Represses Estrogen Receptor   Expression via Induction of the Zinc Finger Protein Blimp1

(2009) X. Wang et al.   MOLECULAR AND CELLULAR BIOLOGY

Revealing Targeted Therapy for Human Cancer by Gene Module Maps

(2008) D. J. Wong et al.   CANCER RESEARCH

miR-206 Expression Is Down-regulated in Estrogen Receptor  -Positive Human Breast Cancer

(2008) N. Kondo et al.   CANCER RESEARCH

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Wilms' Tumor 1 Suppressor Gene Mediates Antiestrogen Resistance via Down-Regulation of Estrogen Receptor-  Expression in Breast Cancer Cells

(2008) Y. Han et al.   MOLECULAR CANCER RESEARCH